Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Change in Receivables: 2019-2025

Historic Change in Receivables for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to $5.2 million.

  • Biodesix's Change in Receivables rose 381.01% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 18.16%. This contributed to the annual value of $1.8 million for FY2024, which is 61.62% down from last year.
  • According to the latest figures from Q3 2025, Biodesix's Change in Receivables is $5.2 million, which was up 2,986.19% from -$181,000 recorded in Q2 2025.
  • Biodesix's 5-year Change in Receivables high stood at $5.2 million for Q3 2025, and its period low was -$13.1 million during Q2 2021.
  • Over the past 3 years, Biodesix's median Change in Receivables value was $325,000 (recorded in 2024), while the average stood at $969,818.
  • As far as peak fluctuations go, Biodesix's Change in Receivables slumped by 5,764.94% in 2021, and later skyrocketed by 7,003.03% in 2024.
  • Over the past 5 years, Biodesix's Change in Receivables (Quarterly) stood at $873,000 in 2021, then declined by 15.69% to $736,000 in 2022, then spiked by 380.98% to $3.5 million in 2023, then plummeted by 71.72% to $1.0 million in 2024, then soared by 381.01% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, -$181,000 for Q2 2025, and -$904,000 during Q1 2025.